Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05055128
Other study ID # CX842A2201
Secondary ID 2020-003319-91
Status Completed
Phase Phase 2
First received
Last updated
Start date August 11, 2021
Est. completion date September 1, 2022

Study information

Verified date October 2023
Source Cinclus Pharma AG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will be conducted in patients with erosive esophagitis due to gastro-esophageal reflux disease (GERD) Los Angeles (LA) grades C or D, and in patients with at least partial symptom response but still endoscopically unhealed (LA grades A or B) after 8 weeks history of standard treatment healing course with PPI, designed to support dose selection for Phase 3 and to investigate safety, tolerability, and healing rates after 4 weeks treatment of X842 or Lansoprazole, and symptom pattern during subsequent 4 weeks treatment with Lansoprazole.


Description:

This is a randomized, double-blind, active comparator-controlled study with a parallel-group design including four arms with X842 and one arm with Lansoprazole. Randomization to one of the treatments with X842 twice daily (BID) 25 mg, 50 mg, 75 mg, 100 mg, or Lansoprazole 30 mg once daily (QD) will be based on a 1:1:1:1:1 scheme. The duration of each patient's participation in the study, including screening, blind treatment period, and open-label treatment period will be approximately 60 days. The patients will be randomized for 4 weeks of double-blind treatment and will be provided with investigational medicinal product for 35 days. All patients will have an endoscopic evaluation after 4 weeks of treatment. Following the endoscopic evaluation, all patients will receive subsequent 4 weeks of open-label treatment with Lansoprazole. Repeated symptom evaluation to detect symptom patterns will be assessed during this period.


Recruitment information / eligibility

Status Completed
Enrollment 248
Est. completion date September 1, 2022
Est. primary completion date September 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Body mass index (BMI) = 18 and = 40 kg/m^2 at screening. 2. Gastro-esophageal reflux disease with endoscopically confirmed esophagitis: - LA grade C or D =7 days before randomization (with or without historical PPI treatment) or - LA grade A or B =7 days before randomization and history of treatment with the standard healing course of PPI for minimum of 8 weeks prior to screening and =7 days of non-treatment during this period and at least partial symptom response during the minimum of 8 weeks of PPI treatment. 3. Willing and able to comply with all aspects of the protocol (including capsule swallowing, diary completion, etc.). 4. Capable of signing informed consent form. Exclusion Criteria: 1. History or presence of any clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disease or disorder. 2. Patients with so-called "alarm features" in symptomatology, like odynophagia, severe dysphagia, bleeding, weight loss, anemia, and blood in stool pointing to a possible malignant disease of the gastrointestinal (GI) tract. 3. Present clinically significant psychiatric diagnosis. 4. History of malignancy of any organ system. 5. Presence of esophageal ulcer, stricture, BarrettĀ“s esophagus or suspected esophagitis secondary to infection, inflammatory disease, ingestion of erosive chemicals or history of any surgical or medical condition which might significantly alter the Gastro-oesophageal reflux disease (GERD) status or the absorption, distribution, metabolism or excretion of drugs. 6. Known severe atrophic gastritis. 7. Any planned major surgery within the duration of the study. 8. History of a positive result for human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), antibody to Hepatitis B core antigen (anti-HBcAg), or antibody to Hepatitis C virus (anti-HCV) or presence of these findings on screening. 9. History of long QTc syndrome (e.g. QTc =450 ms for males and =470 ms for females). 10. Cardiac arrhythmias or any clinically significant abnormalities in the resting 12-lead ECG at the time of screening, as judged by the Investigator. 11. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity. 12. Current or history of alcohol, drug abuse and/or use of anabolic steroids within 2 years prior to screening. 13. Women who are pregnant or breastfeeding. 14. Patients who have previously participated (completed or withdrawn) in this study CX842A2201.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
X842
Patients will receive X842 tablets.
X842 Dummy
Patients will receive matching placebo tablets for X842.
Lansoprazole
Patients will receive Lansoprazole capsule.
Lansoprazole Dummy
Patients will receive matching placebo capsules for Lansoprazole.

Locations

Country Name City State
Bulgaria Medical Centre Asklepii Dupnitsa
Bulgaria Medical Center Medconsult Pleven Pleven
Bulgaria DCC-1 Sliven Plovdiv
Bulgaria MHAT "Kaspela" Plovdiv
Bulgaria Medical Center Prolet EOOD Ruse
Bulgaria Diagnostive Consultative Center-1 Sliven Sliven
Bulgaria Medical Center Hera - Gastroenterology office Sliven
Bulgaria 2-nd MHAT Sofia
Bulgaria DCC XIV Sofia Sofia Sofia-Grad
Bulgaria DCC XIV Sofia Sofia Sofia-Grad
Bulgaria Medical Center Excelsior Sofia Sofia-Grad
Bulgaria Medical Center Excelsior Sofia
Bulgaria Medical Center Hera - Gastroenterology office Sofia
Bulgaria MHAT "Sveti Ivan Rilski" - Sofia Sofia
Bulgaria Medical Center New Rehabilitation Center EOOD Stara Zagora
Bulgaria Medical Center "Biomed 99" Ltd Vidin
Bulgaria Mhat "Hristo Botev" Vratsa
Czechia ResTrial GastroEndo s.r.o. Praha 4
Georgia LTD"Brothers" Batumi Ajaria
Georgia A. Aladashvili clinic LLC Tbilisi
Georgia Emergency Cardiology Center named by acad. G. Chapidze Tbilisi
Georgia LTD Israeli-Georgian Medical Research Clinic "Helsicore" Tbilisi
Georgia LTD TSMU and Ingorokva High Medical Technology University Clinic Tbilisi
Hungary Bekes Megyei Kozponti Korhaz, Dr.Rethy Pal Tagkorhaz Békéscsaba Békés
Hungary ClinExpert Kft. Budapest Pest
Hungary Pannonia Maganorvosi Centrum Kft Budapest
Hungary Szegedi Tudomanyegyetem Általános Orvostudományi Kar Szeged Csongrád
Poland NZOZ "Centrum Medyczne KERMED" Bydgoszcz Kujawsko-pomorskie
Poland Szpital Zakonu Bonifratrow Sw. Jana Bozego w Lodzi Lodz Lódzkie
Poland Oswiecimskie Centrum Badan Klinicznych Medicome Sp. z o.o. Oswiecim
Poland ETG Skierniewice Skierniewice
Poland Twoja Przychodnia - Szczecinskie Centrum Medyczne Szczecin
Poland Centrum Medyczne Melita Medical Wroclaw Dolnoslaskie
Poland EuroMediCare Szpital Specjalistyczny z Przychodnia Wroclaw
Poland EuroMediCare Szpital Specjalistyczny z Przychodnia Wroclaw
Poland ETG Zamosc Zamosc
Serbia Zvezdara University Medical Center Belgrade
Ukraine Oblasna komunalna ustanova "Chernivetska oblasna klinichna likarnia" Chernivtsi Chernivets'ka Oblast'
Ukraine KNP "Odeska oblasna klinichna likarnia" Odeskoi oblasnoi rady" Odesa Odes'ka Oblast'
Ukraine Medychnyi Tsentr TOV "KHELS KLINIK" - viddil Gasrtroenterology, Hepatology and Endocrinology Vinnytsia Vinnyts'ka Oblast'
Ukraine KU "6-A miska klinichna likarnia" Zaporizhzhia Zaporiz'ka Oblast'
United States Genesis Clinical Research - Tampa Tampa Florida

Sponsors (2)

Lead Sponsor Collaborator
Cinclus Pharma AG Parexel

Countries where clinical trial is conducted

United States,  Bulgaria,  Czechia,  Georgia,  Hungary,  Poland,  Serbia,  Ukraine, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Patients With Esophageal Mucosa Healing The healing of erosive esophagitis due to gastro-esophageal reflux disease (GERD) was assessed. It supported the dose selection X842,through the assessment of healing of erosive esophagitis due to GERD based on endoscopic assessment after 4 weeks of treatment. The dose that would lead to having 85% of the patients have esophageal mucosa healing after 4 weeks of treatment. Following the endoscopic evaluation, all patients received subsequent 4 weeks of open-label treatment with lansoprazole. Repeated symptom evaluation was assessed during this period to detect the symptom pattern. Endoscopy evaluation at 4 weeks was based on the level and duration of acid control achieved with X842. Symptom evaluation was assessed using the validated patient-reported outcome (PRO) QOLRAD (Heartburn version) and patient diaries (RESQ-eDiary). Week 4
Secondary Number of Patients With Adverse Events (AEs) The safety and tolerability of the four dose levels of X842 and Lansoprazole were evaluated, where Lansoprazole served as the active comparator. Here TEAE- Treatment-emergent adverse event, ADR- Adverse drug reaction, SAE- Serious adverse event, and AESI- Adverse events of special interest. From Screening (Day -7 to Day 0) until Week 8
Secondary Percentage of Heartburn-Free 24-hour Days Heartburn-free in a 24-hour day was a day where patient reported having no burning feeling or pain behind breast or in center of upper stomach for both morning and evening. Percentage of heartburn-free 24-hour days based on eDiary(Reflux Symptom Questionnaire electronic Diary: RESQ-eDiary) was evaluated. Reflux-related symptom pattern was evaluated during initial 4 weeks of treatment with four dose levels of X842 and with Lansoprazole, and symptom pattern during subsequent additional 4 weeks Lansoprazole treatment in open-label. Modified RESQ-eDiary was validated self-reported questionnaire electronic symptom diary. mRESQ-eD has 3 domains [i.e. Heartburn (min-max: 0-10), Other GERD signs/symptoms (min-max:0-15) and Regurgitations/Reflux (min-max: 0-8)]. Endoscopy followed by lansoprazole administration and symptom evaluation using PRO QOLRAD (Heartburn version) and patient diaries assessed acid control achieved with X842 at 4 weeks. Weeks 1 and 8
Secondary Percentage at Most-mild Heartburn 24-hour Days Heartburn with at most mild symptoms in a 24-hour day was defined as a day where the patient reported having either no symptoms, very mild symptoms, or mild burning feeling or pain behind the breast or in the center of the upper stomach (score between 0-2) for both morning and evening. Heartburn assessed the severity as per the following scores (0=Did not have, 1=Very mild, 2=Mild, 3=Moderate, 4=Moderately severe, 5=Severe). Here higher scores represent the worst outcome, whereas lower scores represent the better outcome. After endoscopic evaluation, patients received lansoprazole, and symptom evaluation was conducted to detect patterns. Endoscopy evaluation at 4 weeks was based on the level and duration of acid control achieved with X842. Symptom evaluation involved the use of validated PRO QOLRAD (Heartburn version) and patient diaries. Weeks 1 and 8
Secondary Investigator Assessment of Symptoms by Frequency and Severity Investigator assessed severity and frequency of patients' heartburn, regurgitation, and dysphagia in 7 days. Assessment included both severity grade (for severity, items were coded: none, mild, moderate, severe where none represented no complaints, severe represented incapacitating symptoms) and frequency (for frequency, a 7-graded Likert scale was used, ranging from none to all of time) of symptoms. Symptoms were scored as follows: none (no complaints), mild (aware of symptom, but easily tolerated), moderate (discomforting symptom, sufficient to cause interference with normal daily activities and/or sleep), severe (incapacitating symptom, with inability to perform normal daily activities and/or sleep). Following endoscopic evaluation, patients received lansoprazole and underwent symptom evaluation using validated PRO QOLRAD (Heartburn version) and patient diaries.Here, for frequency- All of the time and None of the time, and for symptoms- none and severe data has been presented. Weeks 1 and 8
Secondary Change From Baseline in Quality of Life in Reflux and Dyspepsia (QOLRAD) Score Reflux-related symptom pattern was evaluated during initial 4 weeks of treatment with 4 dose levels of X842 and with Lansoprazole, and symptom pattern during subsequent additional 4 weeks of open-label treatment with Lansoprazole. Heartburn version of QOLRAD is a disease-specific instrument containing 25 questions addressing concerns associated with gastrointestinal symptoms. Questions were rated on a seven-grade (1-7) Likert scale, where a score of 1 represented low quality of life, and as score increased, the patient's condition was considered better. Questions were categorized into 5 domains: emotional distress, sleep disturbance, vitality, food/drink problems, and physical/social functioning. The score in each domain was calculated as the mean of all items in that domain. The score ranges from 1 to 175, higher scores mean a better outcome. After endoscopic evaluation, patients received lansoprazole and underwent symptom evaluation using validated PRO QOLRAD and patient diaries. Baseline, Weeks 1, and 8
See also
  Status Clinical Trial Phase
Completed NCT01452776 - Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis Phase 3
Recruiting NCT05587309 - A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis Phase 3
Completed NCT04124926 - Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis Phase 3
Completed NCT01459367 - Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis Phase 3
Completed NCT00228527 - Esomeprazole for Treatment of GERD in Pediatric Patients Phase 4
Completed NCT01499368 - A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients Phase 3
Not yet recruiting NCT04613895 - Treatment Effect According to Timing of Administration of DWP14012 40 mg N/A
Recruiting NCT02615184 - A Study of Dexlansoprazole in Healing and Maintenance of Healed Erosive Esophagitis (EE) in Children Phase 2
Completed NCT02456935 - Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis Phase 3
Completed NCT02028663 - Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis Phase 2
Completed NCT03006874 - Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis Phase 3
Completed NCT02388724 - Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis Phase 3
Completed NCT01865825 - Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)? N/A
Completed NCT02679508 - Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety Phase 4
Recruiting NCT06391177 - A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily Phase 1
Completed NCT05050188 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008 Phase 1
Completed NCT01874535 - Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy Phase 4
Completed NCT00206180 - NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis Phase 4
Completed NCT01642615 - Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents Phase 2
Completed NCT01630746 - A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis Phase 3